Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: Are we there yet?

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 5-6

  Ramirez, Julio A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; APPLIED RESEARCH; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; HOSPITAL PATIENT; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; PATIENT CARE; PRIORITY JOURNAL; SUBSTITUTION THERAPY; THERAPY EFFECT; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; FEMALE; HOSPITALIZATION; HUMANS; MALE; PNEUMONIA, BACTERIAL;

EID: 84872190025     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00093112     Document Type: Editorial

References (5)

1. Engel MF, Postma DF, Hulscher MEJL, et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur Respir J 2013; 41: 123-130.
2. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-1276.
3. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
4. Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722-727.
5. Woolf SH. The meaning of translational research and why it matters. JAMA 2008; 299: 211-213.